The volume’s review article turns its attention to one of the most closely watched corners of modern oncology: antibody-drug conjugates, or ADCs, in colorectal cancer. These engineered molecules combine an antibody that homes in on tumor cells with a potent cytotoxic payload, aiming to concentrate chemotherapy-like killing power on malignant tissue while sparing healthy cells. The authors chart the rapidly evolving clinical landscape of ADCs in colorectal carcinoma, highlighting the recent approval of trastuzumab deruxtecan, known as T-DXd, for HER2-positive disease as a milestone entry into this treatment arena. By dissecting clinical performance, molecular design considerations and future directions, the review positions ADCs as a promising targeted option for colorectal cancer patients whose clinical needs remain unmet by existing therapies.

Structural biology and fragment-based drug design feature prominently among the original research contributions. In one study, researchers used an X-ray fragment screening approach to identify a series of allosteric inhibitors that selectively target adenosine monophosphate deaminase 2, or AMPD2, over other AMPD isozymes. Traditional inhibitors that bind the enzyme’s active site have struggled with poor selectivity, but by iteratively merging and optimizing fragments, the team developed potent compounds that bind a previously uncharacterized allosteric site. The resulting molecules, designated 10g and 10h, offer valuable chemical tools for probing AMPD2’s roles in nucleotide metabolism, energy homeostasis and immune oncology, an area of growing interest as metabolism becomes a central theme in cancer immunology.

Biosensor technology also received a significant upgrade in the volume. A second structural study demonstrated that grating-coupled interferometry, or GCI, provides a powerful platform for characterizing interactions between G protein-coupled receptors and their ligands. Using the adenosine A2A receptor as a model system, the researchers showed that GCI delivers high-quality kinetic data comparable to the established Biacore technology while enabling rapid affinity and thermodynamic profiling from single-concentration injections. The team validated the approach through kinetic fragment screening of a 704-member library, identifying specific binders that were confirmed by nano differential scanning fluorimetry. The work establishes GCI as an information-rich tool for early-stage GPCR drug discovery, a field that accounts for a large share of current pharmaceutical targets.

Perhaps the most striking example of AI’s expanding role comes from a multi-omics study of Mycobacterium avium infection, an insidious pathogen notorious for its persistence in patients with compromised lungs. By integrating single-cell RNA sequencing with machine learning, the researchers mapped the immune landscape of MAV infection and uncovered a monocyte-driven MIF-APP signaling axis that recruits macrophages and locks them into a hyper-inflammatory state. This mechanism helps explain a long-standing paradox: patients mount vigorous inflammation yet fail to clear the pathogen. The computational analysis also yielded a five-gene diagnostic signature with an area under the curve exceeding 0.88, a level of accuracy that could translate into clinically useful tests. In parallel, the team identified Wogonin, a natural product-derived compound, as a potential host-directed therapeutic that targets STAT3 and TNF to break the immune impasse, shifting the treatment strategy from attacking the bacterium directly to reprogramming the host response.

Data mining of previously deposited screening data proved equally productive in the antiviral arena. Applying a computational prioritization strategy to a legacy screen of nearly 300,000 small molecules, researchers identified three distinct chemical scaffolds that inhibit Lassa virus cell entry with potencies as low as 10 nanomolar and strong selectivity over related viruses. Mechanistic work indicated that these compounds act at the membrane fusion stage by targeting pH-sensitive regions of the viral glycoprotein, the molecular machinery the virus uses to slip into cells after being engulfed. The study highlights how combined computational and experimental approaches can extract new value from old data, a strategy that is increasingly attractive as screening datasets accumulate faster than they can be fully analyzed.

Deep learning also made its mark in vaccine development. Researchers unveiled CellVision, a deep learning-based image analysis platform that fully automates viral plaque counting in high-throughput immuno-plaque assays. The system accurately segments fused plaques and distinguishes them from other objects without any manual image review, a task that has traditionally consumed enormous amounts of technician time and introduced inter-operator variability. Integrated into Merck & Co., Inc.’s µPlaque assay to support an investigational dengue vaccine, CellVision outperformed a commercial alternative and sets a new benchmark for AI-powered analysis in antiviral vaccine discovery, where assay throughput and reproducibility directly influence how quickly candidates can advance.

Cancer drug screening gained precision from a tumor-versus-normal comparison strategy aimed at nasopharyngeal carcinoma, an epithelial cancer strongly associated with Epstein-Barr virus. Using high-throughput drug screening against paired EBV-positive and EBV-negative NPC cell lines alongside normal epithelial controls, researchers identified the AKT inhibitor capivasertib as a highly selective anti-NPC agent that spares healthy cells. The compound synergized with platinum-based chemotherapy, enhanced radiosensitivity, and significantly prolonged survival when combined with cisplatin in xenograft models. The results provide a strong rationale for clinical evaluation of capivasertib in advanced nasopharyngeal carcinoma, where treatment options have remained limited.

Even the statistics of drug screening came under scrutiny. A comparative analysis of statistical tests for count data, such as the numbers of cells in different states, found that simple t tests perform as well as or better than specialized count-based methods at maintaining false-positive rates, with no disadvantage in detecting real differences. The findings reassure researchers that converting count data to percentages and analyzing them with t tests is a valid and effective approach under typical wet-lab conditions, a practical conclusion that could simplify analysis pipelines in countless laboratories.

Rounding out the volume, a short communication described a high-throughput time-resolved fluorescence resonance energy transfer, or TR-FRET, assay developed to interrogate the interaction between the immune checkpoint LILRB4, also known as ILT3, and its ligand SCG2. This pathway drives myeloid-mediated immunosuppression in the tumor microenvironment, a major obstacle to effective cancer immunotherapy. Pilot screening identified two compounds, BMS-813160 and PSB-603, that dose-dependently inhibit the interaction with micromolar potency, providing the first small-molecule modulators of the LILRB4-SCG2 axis. Alongside a new homogeneous OMEGA assay for detecting extracellular AGR2, a protein linked to tumor progression, across diverse biological fluids with a dynamic range from 0.02 to 300 nanograms per milliliter, these contributions underscore the volume’s central message: from fragment merging and biosensors to machine learning diagnostics and automated image analysis, the drug discovery toolkit is becoming faster, smarter and more data-driven at every step.

Subject of Research: AI-driven analytics and data-mining strategies for drug discovery

Article Title: AI-driven analytics and data-mining strategies for drug discovery

Article References: AI-driven analytics and data-mining strategies for drug discovery. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: artificial intelligence, drug discovery, SLAS Discovery, machine learning, antibody-drug conjugates, colorectal cancer, Mycobacterium avium, Lassa virus, deep learning, high-throughput screening, nasopharyngeal carcinoma, immune checkpoint